Sildenafil Cmax is the highest observed plasma concentration measured during a pharmacokinetic concentration-time study. It describes the magnitude of the concentration peak rather than when the peak occurs, how much total systemic exposure accumulates or how long a pharmacological effect persists.
Sildenafil labeling provides a useful quantitative reference: after a single 100 mg oral dose in healthy volunteers, peak plasma concentrations were approximately 440 ng/mL in the referenced concentration-time profile. That value is study- and dose-specific rather than a universal Cmax for every sildenafil exposure.
This page focuses on how sildenafil Cmax is measured and interpreted, including its dose relationship, food effects and examples of conditions that can alter peak exposure. Total exposure belongs on the sildenafil AUC page, while duration of pharmacological effect is addressed separately on the sildenafil duration page.
Cmax is the maximum observed concentration of sildenafil in plasma during a defined pharmacokinetic sampling period. Because plasma samples are collected at specific time points, Cmax is the highest measured value rather than necessarily the exact mathematical maximum of a continuous concentration curve.
In sildenafil labeling, a single oral 100 mg dose in healthy volunteers produced a mean concentration-time profile with peak plasma levels of approximately 440 ng/mL. The corresponding peak occurred around the early part of the profile, consistent with the reported fasted Tmax range of 30 to 120 minutes and median of about 60 minutes.
That approximately 440 ng/mL example should not be treated as a fixed sildenafil Cmax. Peak concentration changes with dose, food conditions, metabolic clearance, study population, interacting drugs and other PK factors. Within the broader sildenafil pharmacokinetic framework, Cmax is therefore a contextual exposure parameter.
| Metric | What It Measures | Sildenafil Context |
|---|---|---|
| Cmax | Highest observed plasma concentration | Approximately 440 ng/mL in a referenced single-dose 100 mg healthy-volunteer profile |
| Tmax | Time of the observed maximum concentration | 30–120 minutes in fasted labeling data; median about 60 minutes |
| AUC | Integrated systemic exposure across time | Captures total exposure rather than peak height |
After oral sildenafil administration, plasma concentrations rise as systemic drug input exceeds the combined effects of distribution and elimination. The concentration-time curve reaches a maximum when the balance between continuing input and concentration-lowering processes produces the highest observed plasma value.
Cmax is the vertical coordinate of that peak, while Tmax is its horizontal time coordinate. In the labeling profile following a single 100 mg dose in healthy volunteers, concentrations rise rapidly toward a peak around the first hour and then decline progressively over the following hours.
The peak is therefore one point within a much larger exposure profile. The sildenafil concentration-time guide examines the full rising and declining curve, while this page isolates the interpretation of its maximum concentration.
| Curve Feature | Interpretation |
|---|---|
| Rising phase | Systemic sildenafil concentrations are increasing as input exceeds net removal. |
| Cmax | Highest observed concentration in the sampling profile. |
| Tmax | Time at which the observed Cmax occurs. |
| Post-peak decline | Distribution and elimination exceed continuing systemic input. |
Cmax is sensitive to the rate at which sildenafil enters systemic circulation. Faster drug input can create a steeper concentration rise and a higher peak because more sildenafil reaches plasma before distribution and elimination have had time to reduce the concentration.
However, Cmax is not a pure absorption-rate measurement. Oral bioavailability, distribution and metabolic clearance act simultaneously, so the observed peak reflects the net result of drug entering and leaving the sampled plasma compartment.
Sildenafil's high-fat meal effect illustrates this distinction clearly: slowed absorption reduces the observed Cmax and delays Tmax without making peak concentration itself a direct measure of either total absorption or absolute bioavailability. The upstream absorption processes are covered on the sildenafil absorption page.
| PK Process | Potential Relationship to Cmax |
|---|---|
| Absorption rate | Faster systemic input can increase peak magnitude under otherwise similar conditions. |
| Systemic availability | Influences the amount of unchanged sildenafil entering systemic circulation. |
| Distribution | Moves sildenafil between plasma and tissues and can reduce measured plasma concentration. |
| Clearance | Removes parent sildenafil while absorption is still occurring. |
Cmax and Tmax describe the same observed peak from two different dimensions. Cmax answers how high the sildenafil concentration rises, whereas Tmax answers how long after administration that maximum observed concentration occurs.
Current labeling reports fasted sildenafil Tmax within approximately 30 to 120 minutes, with a median near 60 minutes. Those timing data do not establish a particular Cmax because two concentration-time profiles can peak at similar times while reaching substantially different concentrations.
The food-effect data provide a practical example: a high-fat meal delays mean Tmax by about 60 minutes while reducing mean Cmax by about 29%. Timing and magnitude therefore change together in that condition, but they remain separate PK parameters. Peak timing is examined on the sildenafil Tmax page.
| Feature | Cmax | Tmax |
|---|---|---|
| Primary question | How high is the observed peak? | When does the observed peak occur? |
| Dimension | Concentration | Time |
| Fasted labeling context | Dose- and condition-dependent | 30–120 minutes; median about 60 minutes |
| High-fat meal effect | Mean reduction about 29% | Mean delay about 60 minutes |
Cmax and AUC are complementary measures of sildenafil exposure. Cmax captures the highest observed plasma concentration, whereas AUC integrates concentration across the complete sampled time interval.
A factor that changes sildenafil clearance can affect both measures but not necessarily by the same percentage. For example, in mild-to-moderate hepatic impairment, labeling reports Cmax approximately 47% higher while AUC increased approximately 85%. The differing percentages demonstrate that peak exposure and integrated exposure are not interchangeable.
Similarly, CYP3A inhibition can alter Cmax and AUC by different magnitudes. The sildenafil AUC guide focuses on total systemic exposure and its interpretation.
| Metric | Primary Interpretation | Example |
|---|---|---|
| Cmax | Peak observed plasma concentration | Hepatic impairment: approximately 47% increase in labeling data |
| AUC | Integrated systemic exposure | Same hepatic-impairment comparison: approximately 85% increase |
Cmax describes the maximum measured plasma concentration, whereas absolute bioavailability describes the fraction of an administered dose reaching systemic circulation as unchanged drug. Sildenafil labeling reports mean absolute oral bioavailability of approximately 41%, but that percentage does not specify how high the plasma concentration peak will be.
Peak concentration depends on both the amount of sildenafil entering systemic circulation and the rate at which it arrives relative to distribution and elimination. Two conditions could therefore produce similar overall systemic availability while generating differently shaped curves and different Cmax values.
The high-fat meal example again illustrates this separation because the prominent labeled changes are a delayed Tmax and approximately 29% lower Cmax. Systemic availability itself is treated separately on the sildenafil bioavailability page.
| Concept | Primary Question |
|---|---|
| Cmax | What is the highest observed sildenafil plasma concentration? |
| Bioavailability | What fraction of the dose reaches systemic circulation unchanged? |
| AUC | How much integrated systemic exposure occurs? |
Cmax is conventionally the highest measured concentration in a participant's observed concentration-time data. Pharmacokinetic blood sampling occurs at discrete intervals, so the actual physiological maximum may occur between two scheduled samples.
This matters especially for sildenafil because its peak can occur relatively early after oral administration. Studies intended to characterize Cmax need sufficiently dense sampling around the expected 30-to-120-minute peak window to avoid poorly resolving the maximum.
Analytical sensitivity and study design also contribute to precision. A reported Cmax should therefore be interpreted together with dose, fed or fasted condition, sampling schedule, population and formulation rather than copied as if it were a universal physical constant.
| Study Feature | Potential Impact on Cmax Interpretation |
|---|---|
| Frequent sampling near expected Tmax | Improves resolution of the observed peak. |
| Wide early sampling intervals | Can miss the actual underlying maximum. |
| Analytical variability | Can contribute to measured concentration differences. |
| Dose and study condition | Determine the context in which the reported Cmax is meaningful. |
Sildenafil Cmax varies because peak concentration reflects absorption, bioavailability, distribution and clearance simultaneously. Dose, food, organ function and metabolic inhibition can therefore all change the observed maximum concentration.
Labeling provides several concrete examples. Severe renal impairment, defined in the cited study as creatinine clearance below 30 mL/min, approximately doubled sildenafil Cmax and AUC. Mild-to-moderate hepatic impairment increased sildenafil Cmax by approximately 47%.
Drug interactions can produce still larger changes in peak exposure. Erythromycin increased sildenafil Cmax by approximately 160% in a labeled interaction study, while saquinavir increased it by approximately 140%. These examples belong to the broader sildenafil PK variability framework rather than serving as predictions for every individual.
| Source of Variation | Observed Sildenafil Cmax Context |
|---|---|
| High-fat meal | Mean Cmax approximately 29% lower. |
| Severe renal impairment | Cmax approximately doubled in the cited single-dose study. |
| Mild-to-moderate hepatic impairment | Cmax approximately 47% higher. |
| Erythromycin | Cmax approximately 160% higher in the labeled interaction study. |
| Saquinavir | Cmax approximately 140% higher in the labeled interaction study. |
Food provides one of the clearest sildenafil-specific demonstrations of how Cmax can change without being interpreted in isolation. When conventional sildenafil tablets are taken with a high-fat meal, labeling reports slower absorption, a mean Tmax delay of approximately 60 minutes and a mean Cmax reduction of approximately 29%.
The result is a later and lower observed plasma peak compared with the fasted condition. This illustrates how Cmax is sensitive to the rate and shape of systemic drug input rather than functioning as a simple measure of whether sildenafil was absorbed at all.
The 29% figure applies to the defined food-effect study context and should not be converted directly into a prediction of clinical effect. Quantitative meal effects and their broader interpretation belong on the sildenafil food-effects page.
| Food-Effect Parameter | Labeling Observation |
|---|---|
| Cmax | Mean reduction of approximately 29% with a high-fat meal. |
| Tmax | Mean delay of approximately 60 minutes. |
| Interpretation | Peak becomes later and lower; this does not make Cmax a direct measure of clinical effect. |
Cmax describes the highest observed sildenafil concentration at one point on the PK curve. Once the maximum has occurred, concentration declines according to distribution and elimination processes, so the height of the peak does not determine how long sildenafil remains present.
The labeling example makes this distinction concrete. After a single 100 mg dose in healthy volunteers, peak plasma levels were approximately 440 ng/mL, whereas plasma levels at 24 hours were approximately 2 ng/mL. Those two measurements describe concentration at different parts of the curve rather than the duration of a clinical effect.
Duration also depends on pharmacodynamic relationships and cannot be read directly from either Cmax or a late plasma concentration. Questions about effect persistence belong on the sildenafil duration page, while concentration decline is interpreted through elimination and half-life.
| Concept | What It Describes | What It Does Not Establish |
|---|---|---|
| Cmax | Highest observed plasma concentration | Duration of pharmacological or clinical effect |
| Half-life | Time scale of terminal concentration decline | Exact clinical duration |
| Clinical duration | Persistence of an observed effect | Peak plasma concentration alone |
Cmax is a pharmacokinetic exposure parameter rather than a direct pharmacodynamic endpoint. A percentage increase in sildenafil Cmax should therefore not be translated into the same percentage increase in therapeutic effect, adverse effect or duration.
Labeling itself illustrates why this distinction matters. Although sildenafil exposure changes with dose and several physiological or interaction conditions, physiological responses do not necessarily scale linearly with plasma concentration across the same range.
Interpreting the biological significance of a concentration requires pharmacodynamic data in addition to PK measurements. The exposure-effect relationship belongs on the sildenafil pharmacodynamics page.
| Domain | Example Measure | Primary Focus |
|---|---|---|
| Pharmacokinetics | Cmax | Maximum circulating sildenafil concentration |
| Pharmacodynamics | Biological-response measure | Effect associated with drug exposure |
| Clinical response | Observed clinical outcome | Result influenced by exposure and additional biological factors |
A useful sildenafil Cmax value should always be accompanied by context: dose, formulation, fed or fasted state, study population, sampling design and any interacting factors. An isolated value without those details is difficult to compare across studies.
The approximately 440 ng/mL peak shown after a single 100 mg dose in healthy volunteers is therefore best treated as a labeled reference example, not as a universal expected plasma concentration. Sildenafil pharmacokinetics are described as dose-proportional over the recommended dose range, while food, organ impairment and CYP3A inhibition provide documented examples of how Cmax can shift.
Cmax becomes most informative when read alongside Tmax and AUC: Tmax identifies peak timing, Cmax quantifies peak height and AUC describes integrated exposure. The sildenafil pharmacokinetics hub connects those measures with absorption, metabolism, clearance and half-life.
| Research Question | Most Relevant Metric or Context |
|---|---|
| How high is the observed sildenafil peak? | Cmax |
| When does the peak occur? | Tmax |
| How much integrated exposure occurs? | AUC |
| What changes peak height? | Dose, absorption conditions, clearance and drug interactions |
| How long does an effect persist? | Pharmacodynamic duration, not Cmax alone |
Sildenafil Cmax is the highest observed plasma concentration measured during a pharmacokinetic concentration-time study. It represents peak concentration magnitude rather than peak timing or total exposure.
There is no single universal sildenafil Cmax because the value depends on dose and study conditions. In a labeling concentration-time profile after a single 100 mg oral dose in healthy volunteers, peak plasma levels were approximately 440 ng/mL.
Sildenafil pharmacokinetics are described in labeling as dose-proportional over the recommended dose range, so systemic exposure including peak concentration generally increases with dose under comparable conditions. This is a pharmacokinetic observation rather than dosing guidance.
Yes. In labeling studies, a high-fat meal reduced mean sildenafil Cmax by approximately 29% and delayed mean Tmax by approximately 60 minutes.
Yes. Mild-to-moderate hepatic impairment increased sildenafil Cmax by approximately 47% in labeling data, while severe renal impairment approximately doubled Cmax in the cited single-dose study.
No. Cmax measures peak plasma concentration. Duration and clinical response depend on the later concentration-time profile and pharmacodynamic relationships and cannot be inferred proportionally from Cmax alone.